Incannex Healthcare (IXHL) Return on Sales (2024 - 2025)

Incannex Healthcare (IXHL) posted quarterly Return on Sales of 5.45% for Q2 2025, down 11.0% on a QoQ basis from 4.91% in Q4 2024.

Incannex Healthcare (IXHL) Return on Sales (2024 - 2025) Analysis & Trends

Incannex Healthcare (IXHL) has reported Return on Sales for 2 consecutive years, with 5.45% the latest figure, recorded in Q2 2025.

Quarterly Return on Sales changed N/A year-over-year to 5.45% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 5.45% (changed N/A YoY) and the FY2025 annual result came in at 5.45%, up 993.0% from the prior year.
Return on Sales retreated to 5.45% in Q2 2025 per IXHL's latest filing, from 4.91% in the prior quarter.
Over the last five years, Return on Sales for IXHL reached as high as 0.73% in Q3 2024 and fell as low as 5.45% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	0.00%
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	0.00%
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-0.01%
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	0.00%
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	0.00%
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	0.00%
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	0.00%
10	Incannex Healthcare	3.63 Mn	3.63 Mn	-	-

Download Data